Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crispr Therapeutics Ag (CRSP) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Crispr Therapeutics Ag. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1674416.
Total stock buying since 2016: $293,942,208.
Total stock sales since 2016: $373,417,799.
Total stock option exercises since 2016: $19,239,965.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 4,976,060 | $258,954,140 | 124,854 | $6,280,789 | 157,497 | $0 |
| 2024 | 0 | $0 | 213,469 | $13,804,447 | 210,103 | $2,477,607 |
| 2023 | 0 | $0 | 125,000 | $6,506,300 | 178,754 | $2,390,000 |
| 2022 | 0 | $0 | 150,000 | $9,148,625 | 292,152 | $2,545,901 |
| 2021 | 0 | $0 | 398,877 | $62,188,865 | 382,267 | $2,802,515 |
| 2020 | 0 | $0 | 963,688 | $100,088,841 | 493,985 | $6,475,496 |
| 2019 | 0 | $0 | 459,118 | $21,805,542 | 141,618 | $778,761 |
| 2018 | 724,346 | $16,626,368 | 2,353,910 | $113,098,938 | 185,500 | $1,065,394 |
| 2017 | 0 | $0 | 2,185,156 | $40,495,452 | 285,421 | $704,291 |
| 2016 | 1,311,550 | $18,361,700 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-11-07 | Celgene Corp /de/ (10% Owner) | Sale | 23,000 | 18.54 | 426,420 |
| 2017-11-06 | Celgene Corp /de/ (10% Owner) | Sale | 79,327 | 18.89 | 1,498,487 |
| 2017-11-03 | Celgene Corp /de/ (10% Owner) | Sale | 22,759 | 19.10 | 434,696 |
| 2017-09-05 | Novak Rodger (Chief Executive Officer) | Sale | 3,853 | 20.33 | 78,319 |
| 2017-09-05 | Novak Rodger (Chief Executive Officer) | Option Ex | 3,853 | 1.81 | 6,973 |
| 2017-08-31 | Novak Rodger (Chief Executive Officer) | Sale | 14,617 | 20.87 | 305,071 |
| 2017-08-30 | Kulkarni Samarth (Chief Business Officer) | Sale | 4,000 | 20.00 | 80,000 |
| 2017-08-30 | Novak Rodger (Chief Executive Officer) | Sale | 58,103 | 20.31 | 1,179,955 |
| 2017-08-30 | Novak Rodger (Chief Executive Officer) | Option Ex | 5,722 | 1.81 | 10,356 |
| 2017-08-28 | Kulkarni Samarth (Chief Business Officer) | Sale | 23,154 | 20.09 | 465,163 |
| 2017-08-28 | Novak Rodger (Chief Executive Officer) | Sale | 17,692 | 20.06 | 354,919 |
| 2017-08-28 | Novak Rodger (Chief Executive Officer) | Option Ex | 17,692 | 1.81 | 32,022 |
| 2017-08-28 | Emster Kurt Von | Sale | 88,011 | 19.79 | 1,741,737 |
| 2017-08-25 | Emster Kurt Von | Sale | 14,913 | 19.52 | 291,101 |
| 2017-08-24 | Emster Kurt Von | Sale | 7,868 | 19.23 | 151,301 |
| 2017-08-23 | Emster Kurt Von | Sale | 7,035 | 18.53 | 130,358 |
| 2017-08-22 | Emster Kurt Von | Sale | 10,954 | 18.53 | 202,977 |
| 2017-08-21 | Emster Kurt Von | Sale | 1,250 | 18.51 | 23,137 |
| 2017-08-18 | Emster Kurt Von | Sale | 1,900 | 18.53 | 35,207 |
| 2017-08-17 | Emster Kurt Von | Sale | 13,593 | 18.74 | 254,732 |
| 2017-08-16 | Emster Kurt Von | Sale | 20,548 | 19.27 | 395,959 |
| 2017-08-15 | Emster Kurt Von | Sale | 25,586 | 19.53 | 499,694 |
| 2017-08-14 | Emster Kurt Von | Sale | 29,983 | 19.64 | 588,866 |
| 2017-08-08 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 1,313 | 18.60 | 24,421 |
| 2017-08-08 | Emster Kurt Von | Sale | 19,850 | 18.71 | 371,393 |
| 2017-08-07 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 13,210 | 18.56 | 245,204 |
| 2017-08-07 | Emster Kurt Von | Sale | 15,623 | 18.53 | 289,494 |
| 2017-08-04 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 477 | 18.55 | 8,848 |
| 2017-08-04 | Emster Kurt Von | Sale | 3,068 | 18.50 | 56,758 |
| 2017-08-03 | Emster Kurt Von | Sale | 47,409 | 17.77 | 842,457 |
| 2017-08-01 | Emster Kurt Von | Sale | 264 | 17.50 | 4,620 |
| 2017-07-31 | Emster Kurt Von | Sale | 5,248 | 17.51 | 91,871 |
| 2017-07-28 | Emster Kurt Von | Sale | 400 | 17.65 | 7,059 |
| 2017-07-27 | Emster Kurt Von | Sale | 40,912 | 17.62 | 721,074 |
| 2017-07-26 | Emster Kurt Von | Sale | 23,744 | 17.63 | 418,606 |
| 2017-07-25 | Emster Kurt Von | Sale | 9,186 | 17.52 | 160,938 |
| 2017-07-14 | Emster Kurt Von | Sale | 36,230 | 16.82 | 609,388 |
| 2017-07-13 | Emster Kurt Von | Sale | 33,629 | 16.87 | 567,321 |
| 2017-07-12 | Emster Kurt Von | Sale | 17,872 | 16.60 | 296,675 |
| 2017-07-11 | Emster Kurt Von | Sale | 14,120 | 16.52 | 233,262 |
| 2017-07-05 | Emster Kurt Von | Sale | 4,254 | 16.26 | 69,170 |
| 2017-06-29 | Emster Kurt Von | Sale | 11,610 | 16.52 | 191,797 |
| 2017-06-28 | Emster Kurt Von | Sale | 31,592 | 17.04 | 538,327 |
| 2017-06-27 | Emster Kurt Von | Sale | 33,434 | 17.43 | 582,754 |
| 2017-06-26 | Emster Kurt Von | Sale | 48,001 | 16.83 | 807,856 |
| 2017-06-23 | Emster Kurt Von | Sale | 30,841 | 16.23 | 500,549 |
| 2017-06-22 | Novak Rodger (Chief Executive Officer) | Sale | 10,825 | 15.37 | 166,391 |
| 2017-06-22 | Novak Rodger (Chief Executive Officer) | Option Ex | 10,825 | 1.81 | 19,593 |
| 2017-06-22 | Emster Kurt Von | Sale | 1,527 | 16.21 | 24,752 |
| 2017-06-21 | Novak Rodger (Chief Executive Officer) | Sale | 11,578 | 15.02 | 173,843 |
| 2017-06-21 | Novak Rodger (Chief Executive Officer) | Option Ex | 11,578 | 1.81 | 20,956 |
| 2017-06-20 | Novak Rodger (Chief Executive Officer) | Sale | 3,252 | 15.00 | 48,786 |
| 2017-06-20 | Novak Rodger (Chief Executive Officer) | Option Ex | 3,252 | 1.81 | 5,886 |
| 2017-06-19 | Novak Rodger (Chief Executive Officer) | Sale | 15,392 | 15.00 | 230,880 |
| 2017-06-19 | Novak Rodger (Chief Executive Officer) | Option Ex | 15,392 | 1.81 | 27,859 |
| 2017-06-09 | Novak Rodger (Chief Executive Officer) | Sale | 1,100 | 15.08 | 16,583 |
| 2017-06-09 | Novak Rodger (Chief Executive Officer) | Option Ex | 1,100 | 1.81 | 1,991 |
| 2017-06-08 | Novak Rodger (Chief Executive Officer) | Sale | 4,203 | 15.00 | 63,045 |
| 2017-06-08 | Novak Rodger (Chief Executive Officer) | Option Ex | 4,203 | 1.81 | 7,607 |
| 2017-05-30 | Novak Rodger (Chief Executive Officer) | Sale | 3,650 | 15.02 | 54,830 |
| 2017-05-30 | Novak Rodger (Chief Executive Officer) | Option Ex | 3,650 | 1.81 | 6,606 |
| 2017-05-17 | Novak Rodger (Chief Executive Officer) | Sale | 25,923 | 16.03 | 415,571 |
| 2017-05-17 | Novak Rodger (Chief Executive Officer) | Option Ex | 25,923 | 1.81 | 46,920 |
| 2017-05-16 | Novak Rodger (Chief Executive Officer) | Sale | 24,077 | 16.50 | 397,294 |
| 2017-05-16 | Novak Rodger (Chief Executive Officer) | Option Ex | 24,077 | 1.81 | 43,579 |
| 2017-05-05 | Novak Rodger (Chief Executive Officer) | Sale | 616 | 16.93 | 10,425 |
| 2017-05-05 | Novak Rodger (Chief Executive Officer) | Option Ex | 616 | 1.81 | 1,114 |
| 2017-05-04 | Novak Rodger (Chief Executive Officer) | Sale | 13,191 | 16.37 | 215,963 |
| 2017-05-04 | Novak Rodger (Chief Executive Officer) | Option Ex | 13,191 | 1.81 | 23,875 |
| 2017-05-03 | Novak Rodger (Chief Executive Officer) | Sale | 20,269 | 16.34 | 331,296 |
| 2017-05-03 | Novak Rodger (Chief Executive Officer) | Option Ex | 20,269 | 1.81 | 36,686 |
| 2017-05-02 | Novak Rodger (Chief Executive Officer) | Sale | 15,924 | 16.53 | 263,239 |
| 2017-05-02 | Novak Rodger (Chief Executive Officer) | Option Ex | 15,924 | 1.81 | 28,822 |
| 2017-05-01 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 1,852 | 16.61 | 30,754 |
| 2017-04-28 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 4,912 | 16.62 | 81,637 |
| 2017-04-27 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 13,527 | 16.84 | 227,794 |
| 2017-04-27 | Kulkarni Samarth (Chief Business Officer) | Sale | 2,206 | 16.78 | 37,023 |
| 2017-04-27 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 2,206 | 1.81 | 3,992 |
| 2017-04-26 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 3,200 | 16.76 | 53,641 |
| 2017-04-26 | Kulkarni Samarth (Chief Business Officer) | Sale | 3,275 | 16.74 | 54,816 |
| 2017-04-26 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 3,275 | 1.81 | 5,927 |
| 2017-04-25 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 4,800 | 16.87 | 80,990 |
| 2017-04-25 | Kulkarni Samarth (Chief Business Officer) | Sale | 5,115 | 16.87 | 86,290 |
| 2017-04-25 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 5,115 | 1.81 | 9,258 |
| 2017-04-24 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 3,522 | 16.44 | 57,898 |
| 2017-04-24 | Kulkarni Samarth (Chief Business Officer) | Sale | 3,500 | 16.46 | 57,620 |
| 2017-04-24 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 3,500 | 1.81 | 6,335 |
| 2017-04-21 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 3,010 | 17.02 | 51,221 |
| 2017-04-21 | Kulkarni Samarth (Chief Business Officer) | Sale | 3,000 | 17.01 | 51,033 |
| 2017-04-21 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 3,000 | 1.81 | 5,430 |
| 2017-04-20 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 2,937 | 17.37 | 51,024 |
| 2017-04-20 | Kulkarni Samarth (Chief Business Officer) | Sale | 2,800 | 17.36 | 48,621 |
| 2017-04-20 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 2,800 | 1.81 | 5,068 |
| 2017-04-20 | Novak Rodger (Chief Executive Officer) | Sale | 2,294 | 17.37 | 39,851 |
| 2017-04-20 | Novak Rodger (Chief Executive Officer) | Option Ex | 2,294 | 1.81 | 4,152 |
| 2017-04-19 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 7,240 | 18.04 | 130,587 |
| 2017-04-19 | Kulkarni Samarth (Chief Business Officer) | Sale | 7,258 | 18.04 | 130,927 |
| 2017-04-19 | Kulkarni Samarth (Chief Business Officer) | Option Ex | 7,258 | 1.81 | 13,136 |
| 2017-04-19 | Novak Rodger (Chief Executive Officer) | Sale | 47,706 | 18.09 | 862,906 |
| 2017-04-19 | Novak Rodger (Chief Executive Officer) | Option Ex | 47,706 | 1.81 | 86,347 |
| 2016-10-24 | Lundberg Sven Ante (Chief Scientific Officer) | Buy | 400 | 14.00 | 5,600 |
| 2016-10-24 | Woiwode Thomas (Director) | Buy | 161,000 | 14.00 | 2,254,000 |
| 2016-10-24 | George Simeon | Buy | 66,500 | 14.00 | 931,000 |
| 2016-10-24 | Bolzon Bradley J Phd (Director) | Buy | 161,000 | 14.00 | 2,254,000 |
| 2016-10-24 | Emster Kurt Von (Director) | Buy | 56,000 | 14.00 | 784,000 |
| 2016-10-24 | Glaxosmithkline Plc | Buy | 66,500 | 14.00 | 931,000 |
| 2016-10-24 | Celgene Corp /de/ (10% Owner) | Buy | 800,150 | 14.00 | 11,202,100 |
Insider trading activities including stock purchases, stock sales, and option exercises of CRSP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Crispr Therapeutics Ag (symbol CRSP, CIK number 1674416) see the Securities and Exchange Commission (SEC) website.